Arcadia Biosciences, Inc.
RKDA
$3.40
-$0.0813-2.34%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 6.65% | -4.27% | -14.79% | -37.93% | -48.32% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.65% | -4.27% | -14.79% | -37.93% | -48.32% |
| Cost of Revenue | -1.40% | -23.94% | -29.04% | -60.33% | -58.78% |
| Gross Profit | 20.06% | 42.47% | 15.74% | 122.20% | -10.54% |
| SG&A Expenses | -15.73% | -32.42% | -40.26% | -35.49% | -33.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.90% | -30.75% | -38.01% | -43.00% | -40.96% |
| Operating Income | 21.92% | 41.00% | 47.68% | 45.65% | 36.81% |
| Income Before Tax | 77.67% | 85.59% | 97.72% | 34.06% | 42.73% |
| Income Tax Expenses | -50.00% | -53.33% | -42.86% | -42.86% | 600.00% |
| Earnings from Continuing Operations | 77.63% | 85.55% | 97.67% | 34.07% | 42.65% |
| Earnings from Discontinued Operations | 35.29% | -20.28% | -247.55% | -294.19% | -849.75% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -100.00% | -100.00% | -95.61% | -97.88% | -79.16% |
| Net Income | 62.09% | 56.73% | 65.37% | 9.07% | 24.70% |
| EBIT | 21.92% | 41.00% | 47.68% | 45.65% | 36.81% |
| EBITDA | 20.95% | 41.40% | 48.19% | 45.85% | 36.36% |
| EPS Basic | 76.80% | 76.51% | 81.99% | 44.96% | 49.19% |
| Normalized Basic EPS | 61.01% | 72.55% | 99.84% | 50.64% | 30.40% |
| EPS Diluted | 76.80% | 76.51% | 81.99% | 44.96% | 49.19% |
| Normalized Diluted EPS | 61.01% | 72.55% | 99.84% | 50.64% | 30.40% |
| Average Basic Shares Outstanding | 28.05% | 55.13% | 101.02% | 106.24% | 86.80% |
| Average Diluted Shares Outstanding | 28.05% | 55.13% | 101.02% | 106.24% | 86.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
